Navigation Links
Positive Data from Arena Pharmaceuticals' Pivotal BLOOM Trial Demonstrate that Lorcaserin Significantly Improved Markers of Cardiovascular Risk and Glycemic Parameters and was not Associated with Depression or Suicidal Ideation
Date:10/25/2009

A standardized program of moderate diet and exercise guidance is included in the Phase 3 program. The program's hierarchically ordered co-primary efficacy endpoints are: the proportion of patients achieving 5% or greater weight loss after 12 months, the difference in mean weight loss compared to placebo after 12 months, and the proportion of patients achieving 10% or greater weight loss after 12 months. Arena is also studying several key secondary endpoints, including changes in serum lipids, markers of inflammation and insulin resistance, and in the BLOOM-DM trial, other indicators of glycemic control.

About Lorcaserin

Lorcaserin is a novel single agent that represents the first in a new class of selective serotonin 2C receptor agonists. The serotonin 2C receptor is expressed in the brain, including the hypothalamus, an area involved in the control of appetite and metabolism. Stimulation of this receptor is strongly associated with feeding behavior and satiety. Arena has patents that cover lorcaserin in the US and other jurisdictions, which in most cases are capable of continuing into 2023 without taking into account any patent term extensions or other exclusivity Arena might obtain.

About Weight Management

The National Institutes of Health reported in 2007 that about 65% of US adults are overweight or obese. A 2009 publication in Health Affairs estimated the annual medical burden of obesity in the US to be $147 billion in 2008. Studies have shown that weight loss of 5% to 10% is medically significant and results in meaningful improvements in cardiovascular risk factors and a significant reduction in the incidence of type 2 diabetes in patients with glucose intolerance.

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, centr
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. UCLA/RAND study shows that many children of HIV-positive parents are not in their custody
3. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
4. Nutrition model stresses positive experience of eating
5. Ultrasound plus mammography finds more cancers, but increases false positives
6. Oncolytics Biotech Inc. reports positive interim results of UK phase Ia/Ib trials
7. PEAK Surgical Announces Positive Surgical Incision Wound Healing Results With the PEAK PlasmaBlade(TM)
8. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
9. Evotec Reports Positive Top-Line Results in Phase II Study With EVT 201 in Elderly Insomniacs With Daytime Sleepiness
10. A low prevalence of H pylori in HIV-positive patients
11. Drug Company-Funded Asthma Drug Studies More Positive
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2015)... Washington, D.C. (PRWEB) April 25, 2015 ... supporters worldwide will join The Million Nets Pledge, a ... Nets campaign to protect refugee families with one million ... on their increased work with UN partners to protect ... Africa from malaria. , “There has been a ...
(Date:4/25/2015)... April 25, 2015 By definition, a CIO’s ... for the enterprise relying on their judgement and expertise to ... But according to an article published in National Mortgage ... actually be doing a disservice to their responsibilities by focusing ... and t’s are crossed when it comes to company policy ...
(Date:4/25/2015)... 2015 The URO CENTER of NEW YORK ... chosen by the New York Academy of Medicine to receive ... the field of Urology. , Dr. Ferdinand Valentine, born in ... diseases. He was a man of rare and attractive ... Not only did he devote his life to his ...
(Date:4/24/2015)... NY (PRWEB) April 24, 2015 Constellations ... living residence in Westchester County. Just 35 miles from ... transition individuals back into everyday life while recovering from ... May 7, 2015, will allow therapists, doctors and treatment ... and learn more about the opportunities offered by Constellations ...
(Date:4/24/2015)... 24, 2015 The Fastest Fat Loss Week ... great success of the Xtreme Fat Loss Diet, has been ... fat loss blueprint that claims to help one lose belly ... HealthyandFitZone.com's Stan Stevenson, prompting an investigative review. , "Our ... creators spent years researching and experimenting with these methods on ...
Breaking Medicine News(10 mins):Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 2Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 3Health News:Supporters Worldwide Join The Million Nets Pledge on World Malaria Day 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 2Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 3Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 4Health News:An Outsider’s Perspective on Cyber Security Can Only Benefit CIOs 5Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 2Health News:The 2015 Valentine Award Comes From The Heart and Goes To Famous New York Urologist 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Fastest Fat Loss Week Ever Review Revealed on Healthy & Fit Zone 2
... 12 InfuSystem Holdings, Inc.,(OTC Bulletin Board: INHI; ... and associated clinical services, today announced,financial results and ... of,2008., Mr. Steve Watkins, chief executive officer, ... first full quarter of operations as a stand-alone,public ...
... Medical Association (AVMA) has revised its policy on ... additional guidance,for managing pain associated with these procedures. ... not dictate that practitioners use any,particular method of ... recommendations for consideration by practitioners when they work,with ...
... The American Veterinary,Medical Association (AVMA) has reinforced its ... and other equines by approving a,new policy on the ... the AVMA Executive Board on April 12, 2008,states that ... opposes the,use of double-deck trailers to transport equines. The ...
... Regulatory Authority Over Tobacco, WASHINGTON, May 9 ... country, today announces their,support of H.R. 1108, "The ... gives FDA regulatory authority over tobacco products., ... this year.,H.R. 1108 has broad bi-partisan support and ...
... N.H., May 12 Atrium Medical Corporation ... and precautionary recall of,selected lots of HYDRAGLIDE(TM) ... Atrium heparin-coated Hydraglide Thoracic,Catheters were manufactured with ... chondroitin sulfate (OSCS). The patient risk associated,with ...
... community observes,the destructive aftermath of the world,s second ... mounting frustration over getting humanitarian aid,for cyclone victims, ... been proactive-and more importantly, successful-in initiating,medical care at ... 100,000 people,are assumed dead. AMIMA has funded the ...
Cached Medicine News:Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 2Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 3Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 4Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 5Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 6Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 7Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 8Health News:InfuSystem Holdings Provides Business Update and Comments on First Quarter 2008 Financial Results 9Health News:Revised AVMA Policy on Castrating and Dehorning Cattle Provides Additional Guidance for Managing Pain 2Health News:AVMA Opposes Use of Double-Deck Trailers for Transporting Horses and Other Equines 2Health News:Atrium Initiates Voluntary Recall Action Regarding HYDRAGLIDE(TM) Brand Heparin-Coated Thoracic Drainage Catheters Used for Autotransfusion During Cardiopulmonary Bypass Surgery 2Health News:Alumni Myanmar Institutes of Medicine Association (AMIMA) Races Time to Help Cyclone Victims 2
(Date:4/24/2015)... , April 24, 2015  Lannett Company, Inc. ... amended and increased its five-year revolving credit facility to ... an accordion feature that will allow the company to ... additional $30.0 million, subject to securing additional commitments from ... of the credit facility remains December 18, 2018.   ...
(Date:4/24/2015)... Spain , April 24, 2015  Elekta has ... Monaco® treatment planning system , enabling European clinics ... supports major treatment techniques including advanced 3D planning, IMRT, ... system. Monaco ... as well improved workflow efficiency. Advancements in 3D planning ...
(Date:4/23/2015)... April 23, 2015  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, today reported net income for ... $1.12 per diluted share.  Net income for the same ... per diluted share, and non-GAAP net income was $82.1 ... sales for the quarter ended March 31, 2015 increased 13.0 ...
Breaking Medicine Technology:Lannett Expands Revolving Credit Facility To $120 Million 2Elekta CE marks for Monaco v5.10 treatment planning system 2Edwards Lifesciences Reports First Quarter Results 2Edwards Lifesciences Reports First Quarter Results 3Edwards Lifesciences Reports First Quarter Results 4Edwards Lifesciences Reports First Quarter Results 5Edwards Lifesciences Reports First Quarter Results 6Edwards Lifesciences Reports First Quarter Results 7Edwards Lifesciences Reports First Quarter Results 8Edwards Lifesciences Reports First Quarter Results 9Edwards Lifesciences Reports First Quarter Results 10Edwards Lifesciences Reports First Quarter Results 11Edwards Lifesciences Reports First Quarter Results 12Edwards Lifesciences Reports First Quarter Results 13Edwards Lifesciences Reports First Quarter Results 14Edwards Lifesciences Reports First Quarter Results 15Edwards Lifesciences Reports First Quarter Results 16
... Inc., (IBI), a privately held biopharmaceutical company that ... ophthalmic pharmaceuticals, today announced that Wendy Yee Murahashi, ... as Vice-President, Clinical Development.  Dr. Murahashi will lead ... proprietary Verisome® drug delivery technology. ...
... 2011 Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ... and chief operating officer, is scheduled to present a ... in New York City on Wednesday, December 14th at ... http://photos.prnewswire.com/prnh/20030226/RIGLLOGO ) To access the live ...
Cached Medicine Technology:Icon Appoints Murahashi Vice President, Clinical Development 2